Abstract
Immunotherapy is a promising option for cancer treatment that might cure cancer with fewer side effects by primarily activating the host's immune system. However, the effect of traditional immunotherapy is modest, frequently due to tumor escape and resistance of multiple mechanisms. Pharmaceutical nanotechnology, which is also called cancer nanotechnology or nanomedicine, has provided a practical solution to solve the limitations of traditional immunotherapy. This article reviews the latest developments in immunotherapy and nanomedicine, and illustrates how nanocarriers (including micelles, liposomes, polymer–drug conjugates, solid lipid nanoparticles and biodegradable nanoparticles) could be used for the cellular transfer of immune effectors for active and passive nanoimmunotherapy. The fine engineering of nanocarriers based on the unique features of the tumor microenvironment and extra-/intra-cellular conditions of tumor cells can greatly tip the triangle immunobalance among host, tumor and nanoparticulates in favor of antitumor responses, which shows a promising prospect for nanoimmunotherapy.
References
- 1 Cancer Facts & Figures 2012. www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012.
- 2 . Cancer immunotherapy – revisited. Nat. Rev. Drug Discov. 10(8), 591–600 (2011).
- 3 . Cancer immunotherapy. Cancer Biother. Radiopharm. 26(1), 1–64 (2011).
- 4 Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
- 5 Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196–200 (2002).
- 6 . T-cell growth factor. Immunol. Rev. 51, 337–357 (1980).
- 7 . Immunology: improving on nature in the twenty-first century. Cell 100(1), 129–138 (2000).
- 8 . Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1), 53–58 (2012).
- 9 . Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know. Nat. Rev. Clin. Oncol. 8(10), 577–585 (2011).
- 10 . Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991–998 (2002).
- 11 . The tumor dormant state. Adv. Cancer Res. 34, 107–140 (1981).
- 12 . The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
- 13 . Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21(9), 455–464 (2000).
- 14 Nano polymeric carrier fabrication technologies for advanced antitumor therapy. Biomed. Res. Int. 2013, 305089 (2013).
- 15 . Opportunities and challenges in vaccine delivery. Eur. J. Pharm. Sci. 36(4–5), 605–608 (2009).
- 16 . Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 2011, 732413 (2011).
- 17 . Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471–7478 (2009).
- 18 . Oncogene addiction. Curr. Biol. 22(2), R43–R44 (2012).
- 19 . Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin. Cancer Res. 15(24), 7492–7501 (2009).
- 20 . Immune regulatory antibodies: are they the next advance? Cancer J. 16(4), 311–317 (2010).
- 21 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
- 22 . Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol. Ther. 138(3), 452–469 (2013).
- 23 . Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 299(2), 267–278 (2004).
- 24 Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. Int. J. Nanomedicine 7, 4661–4677 (2012).
- 25 . Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 6(5), 797–808 (2007).
- 26 . A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother. 57(4), 517–530 (2008).
- 27 . Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol. 82(6), 644–650 (2004).
- 28 . Virus-like particles in vaccine development. Expert Rev. Vaccines 9(10), 1149–1176 (2010).
- 29 . Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909–915 (2004).
- 30 . Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3(8), 630–641 (2003).
- 31 . Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095–1107 (2010).
- 32 Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnol. Bioeng. 104(4), 674–686 (2009).
- 33 . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263–274 (2005).
- 34 . Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295–307 (2006).
- 35 . Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8(3), 277–284 (2007).
- 36 Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int. J. Nanomedicine 6, 1991–2005 (2011).
- 37 . Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 732413 (2011).
- 38 . Polymeric nanoparticulates for cancer immunotherapy. Nanomedicine (Lond.) 8(5), 679–682 (2013).
- 39 The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy. Mini Rev. Med. Chem. 13(5), 643–652 (2013).
- 40 Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 33(21), 5349–5362 (2012).
- 41 Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano 7(3), 2042–2055 (2013).
- 42 Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells. Nanotoxicology 5(4), 606–621 (2011).
- 43 Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
- 44 Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 178(5), 2979–2986 (2007).
- 45 . Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J. Med. Virol. 80(1), 11–19 (2008).
- 46 Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26(10), 1303–1313 (2008).
- 47 . Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28(23), 3427–3436 (2007).
- 48 . Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J. Biomed. Mater. Res. A 81(3), 652–662 (2007).
- 49 . Chemical adjuvants for plasmid DNA vaccines. Vaccine 25(19), 3731–3741 (2007).
- 50 Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 62(2), 285–297 (2013).
- 51 . Mannosylated polyethylenimine coupled mesoporous silica nanoparticles for receptor-mediated gene delivery. Int. J. Pharm. 359(1–2), 280–287 (2008).
- 52 . Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine 6(1), 110–118 (2010).
- 53 Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine 25(7), 1316–1327 (2007).
- 54 Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119(8), 2231–2244 (2009).
- 55 . Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug. Chem. 20(2), 241–248 (2009).
- 56 . Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length. J. Control. Release 142(2), 229–237 (2010).
- 57 . Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization. Acta Biomater. 8(9), 3210–3217 (2012).
- 58 Development of tripartite polyion micelles for efficient peptide delivery into dendritic cells without altering their plasticity. J. Control. Release 154(2), 156–163 (2011).
- 59 . Multifunctional triblock copolymers for intracellular messenger RNA delivery. Biomaterials 33(28), 6868–6876 (2012).
- 60 Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27(23), 3013–3021 (2009).
- 61 Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26(39), 5046–5057 (2008).
- 62 . Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5(6), 703–724 (2008).
- 63 Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10(3), 243–251 (2011).
- 64 . Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol. Pharm. 8(4), 1266–1275 (2011).
- 65 . Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J. Control. Release 105(3), 199–212 (2005).
- 66 . Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 1770(4), 681–686 (2007).
- 67 Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9(7), 572–578 (2010).
- 68 . Uptake of antigen encapsulated in polyethylcyanoacrylate nanoparticles by D1-dendritic cells. Pharmazie 59(2), 134–142 (2004).
- 69 . “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J. Immunother. 30(4), 378–395 (2007).
- 70 Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J. Control. Release 138(2), 113–121 (2009).
- 71 . Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28(35), 5344–5357 (2007).
- 72 Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147(3), 342–349 (2010).
- 73 . Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 31(2–3), 293–315 (2008).
- 74 . Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies. J. Microencapsul. 29(7), 615–625 (2012).
- 75 . Controlled antibody delivery systems. Biotechnology (NY) 10(11), 1446–1449 (1992).
- 76 Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool. PLoS ONE 6(4), e18268 (2011).
- 77 Intracellular protein delivery by hollow mesoporous silica capsules with a large surface hole. Nanotechnology 23(8), 085101 (2012).
- 78 Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J. Am. Chem. Soc. 132(20), 6906–6907 (2010).
- 79 . Materials engineering for immunomodulation. Nature 462(7272), 449–460 (2009).
- 80 Efficient delivery of bioactive antibodies into the cytoplasm of living cells by charge-conversional polyion complex micelles. Angew. Chem. Int. Ed. Engl. 49(14), 2552–2555 (2010).
- 81 Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells. FASEB J. 27(1), 98–108 (2013).
- 82 . Light activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol. Pharm. 10(8), 2858–2867 (2013).
- 83 . Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6(Pt 1), 688–701 (2006).
- 84 Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody–polymer conjugate. Mol. Pharm. 9(12), 3506–3514 (2012).
- 85 . A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. Bioconjug. Chem. 13(5), 996–1001 (2002).
- 86 Novel dual-control poly(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug release. Nanomedicine (Lond.) 7(3), 383–392 (2012).
- 87 . Materials engineering for immunomodulation. Nature 462(7272), 449–460 (2009).
- 88 Global medical discovery. The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy. http://globalmedicaldiscovery.com/key-scientific-articles/the-finely-regulating-well-defined-functional-polymeric-nanocarriers-for-anti-tumor-immunotherapy.
- 89 . The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58(7), 1408–1416 (1998).
- 90 . Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99(19), 1441–1454 (2007).
- 91 . Relationship between microvessel density and thermographic hot areas in breast cancer. Surg. Today 33(4), 243–248 (2003).
- 92 . Tailoring polymeric micelles to optimize delivery to solid tumors. Nanomedicine (Lond.) 7(8), 1235–1252 (2012).
- 93 . Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Deliv. Rev. 56(8), 1161–1176 (2004).
- 94 . Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863), 627–630 (2008).
- 95 . The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 146(3), 264–275 (2010).
- 96 . Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew. Chem. Int. Ed. Engl. 49(8), 1451–1455 (2010).
- 97 . Block copolymer micelles for nanomedicine. Nanomedicine (Lond.) 7(2), 169–172 (2012).
- 98 . Effect of block compositions of amphiphilic block copolymers on the physicochemical properties of polymeric micelles. Polymer 52(17), 3783–3790 (2011).
- 99 The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials 32(15), 3832–3844 (2011).
- 100 . A comparative study of chain dynamics of di-and tri-block copolymers in semidilute solution in a non-selective solvent. Chinese J. Polym. Sci. 22(6), 589–598 (2004).
- 101 . Principles of Polymerization (Chemistry) (4th Edition). Wiley-Blackwell Hobroke, NJ, USA (2004).
- 102 . Direct evaluation of DLVO theory for predicting long-range forces between a yeast cell and a surface. Langmuir 21(18), 8198–8203 (2005).
- 103 . Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930–4934 (2006).
- 104 . Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25(8), 1815–1821 (2008).
- 105 . Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9(2), E128–E147 (2007).
- 106 . Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22(19), 2406–2412 (2004).
- 107 . Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751–760 (2007).
- 108 . Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm. Res. 26(1), 72–81 (2009).
- 109 The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials 30(2), 233–241 (2009).
- 110 . Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 491(1), 5–12 (2008).
- 111 . siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew. Chem. Int. Ed. Engl. 46(12), 2023–2027 (2007).
- 112 . Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16(1), 122–130 (2005).
- 113 . Smart polymeric micelles for gene and drug delivery. Drug Discov. Today Technol. 2(1), 21–26 (2005).
- 114 . Recent progress in tumor pH targeting nanotechnology. J. Control. Release 132(3), 164–170 (2008).
- 115 . Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 5(2), 325–329 (2005).
- 116 PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J. Am. Chem. Soc. 130(18), 6001–6009 (2008).
- 117 Amphiphilic core-shell nanoparticles with poly(ethylenimine) shells as potential gene delivery carriers. Bioconjug. Chem. 16(1), 139–146 (2005).
- 118 Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32(14), 3666–3678 (2011).
- 119 . Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev. 61(3), 205–217 (2009).
- 120 . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771–782 (2008).
- 121 Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9(7), 572–578 (2010).
- 122 Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 3(7), 423–428 (2008).
- 123 . Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469–478 (2007).
- 124 . Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta 1590(1–3), 131–139 (2002).
- 125 . Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61(3), 1095–1099 (2001).
- 126 Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 30(3), 322–328 (2012).
- 127 Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 179(5), 2860–2869 (2007).
- 128 . Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 6(3), 401–418 (2007).